Dermatology
Dermatology guidance, immune pathway mechanisms and clinical updates across inflammatory skin disease, biologics and targeted therapy.
Latest Guidelines
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
This NICE publication is marked as a terminated appraisal, so it functions as a status notice rather than an active treatment recommendation for routine care. If…
Hidradenitis Suppurativa: Assessment and Management (NICE NG73)
Diagnose hidradenitis suppurativa clinically based on recurrent painful nodules, abscesses, sinus tracts, and scars localised to intertriginous areas (axillae, groin, inframammary folds), then assess severity using…
Non-Melanoma Skin Cancer: Diagnosis and Management (NICE NG12)
Refer suspected BCC or SCC to specialist dermatology using 2-week wait pathway if diagnosis is clear; use urgent referral for lesions >4 mm depth, poorly demarcated,…
Acne Vulgaris: Management (NICE NG198)
Prescribe topical benzoyl peroxide monotherapy for mild facial acne; for mild-to-moderate acne, combine benzoyl peroxide with a topical retinoid or topical antibiotic Prescribe oral antibiotics (doxycycline…
Atopic Eczema in Under 12s: Diagnosis and Management (NICE NG190)
Diagnose atopic eczema clinically based on itching, typical morphology and distribution, onset before age 2 years, and history of dry skin or atopic disease; no diagnostic…
Psoriasis: Assessment and Management (NICE NG10)
Assess psoriasis severity using BSA, PASI, or clinical judgement; classify as mild (
Trial Radar
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to…
PHASE1A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Early-stage trial testing new drug SYX-5219 for safety and effectiveness in healthy people and atopic dermatitis patients.
PHASE3A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
52-week trial testing whether continuing or increasing ritlecitinib dosing maintains or improves skin pigmentation recovery in non-segmental vitiligo…
NAA Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults
Trial testing whether a yeast-based spray reduces underarm odor compared to placebo in healthy adults.
Clinical News
Hundreds contact BBC about mystery skin condition ‘hell’ – but doctors can’t agree it exists
Doctors remain divided on whether a severe skin condition reported by hundreds of patients represents extreme eczema or…
29 Mar 2026Our skin is falling off and no-one can tell us why
Topical Steroid Withdrawal: Key Clinical Takeaways TSW is now subject to formal UK research: Growing social media documentation…
24 Feb 2026Tens of thousands with vitiligo to be offered “life-changing” new cream on NHS to restore skin colour
Tens of thousands of people living with vitiligo affecting their face are to be offered the first approved…
27 Oct 2025Isotretinoin – updates to prescribing guidance and survey of services
The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismIL-4/IL-13 Axis
IL-4/IL-13 Axis is a clinically relevant Drug Science explainer. Interleukin-4 (IL-4) and interleukin-13 (IL-13) are hallmark type 2 cytokines produced…
MechanismJAK-STAT Pathway
JAK-STAT Pathway is a clinically relevant Drug Science explainer. The Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway is…
MechanismThe IL-17/IL-23 Axis
The IL-17/IL-23 Axis is a clinically relevant Drug Science explainer. The IL-23/IL-17 axis is a central driver of immune-mediated inflammatory…
MechanismTNF-α Signalling
TNF-α Signalling is a clinically relevant Drug Science explainer. Tumour necrosis factor-alpha (TNF-α) is a pleiotropic pro-inflammatory cytokine produced predominantly…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Dermatology podcasts, webinars and CPD modules will appear here as new education is published and tagged.
Useful starting points in Dermatology
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to…
TrialA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Early-stage trial testing new drug SYX-5219 for safety and effectiveness in healthy people and atopic dermatitis patients.
TrialA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
52-week trial testing whether continuing or increasing ritlecitinib dosing maintains or improves skin pigmentation recovery in non-segmental vitiligo…
Education that still supports this area
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
PodcastJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk…
Follow Dermatology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Dermatology
Choose guideline, trial, Drug Science and education updates for this specialty.